AstraZeneca And Sanofi March Ahead With Positive Phase III RSV Data
MELODY Data Music To Companies’ Ears
Executive Summary
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.
You may also be interested in...
EU To Sue AstraZeneca Over Vaccine Delivery: Can Either Side Win?
The legal challenge is risky for the European Commission, with AZ’s contract only binding it to make ‘best reasonable efforts’ to deliver vaccines to schedule.
Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion
Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.
Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine
Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.